Gregory L Weaver has bought stock on 3 days since Mar 2018

Gregory L. Weaver is the Chief Financial Officer of Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company developing peptide-based therapeutics such as pemvidutide for obesity and MASH, a position he assumed in November 2024.( With over 25 years of finance experience in life sciences, he previously served as CFO at Cognito Therapeutics (2023-2024), focusing on neurodegenerative diseases, and at atai Life Sciences (2020-2022), where he led a $225 million IPO.(

Weaver's career highlights include CFO roles at multiple public biotech firms, such as Sirna Therapeutics (acquired by Merck), ILEX Oncology (acquired by Genzyme), Eloxx Pharmaceuticals (2017-2020), and others like Atossa Therapeutics, Liminal BioSciences, and Poniard Pharmaceuticals.( He currently serves as a Director and Chair of the Audit Committee at BioIntelliSense, Director at Centenara Labs, and Vice-Chairman at HarborPath, a non-profit aiding medication access.( A U.S. Air Force veteran, he holds a B.A. in Accounting and Finance from Trinity University and an MBA from Boston College.( Recently, he purchased 10,000 shares of ALT on March 13, 2025, at $5.20 and 5,000 shares on March 6, 2026, at $3.54.(

Written by Perplexity from public sources.